Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs

Epilepsia

Volumn 40, Issue SUPPL. 5, 1999, Pages s2-s10

  White, H Steve ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Antiepileptic drugs; Felbamate; GABA; Gabapentin; Glutamate; Ion channels; Lamotrigine; Oxcarbazepine; Tiagabine; Topiramate; Vigabatrin; Zonisa mide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; EPILEPSY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032848061     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00913.x     Document Type: Review

References (69)

1. Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937; 85:525-6.
2. White HS, Wolf HH, Woodhead JH, Kupferberg HJ. The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy. In: French J, Leppik I, Dichter MA, eds. Antiepileptic drug development. Advances in neurology. Vol. 76. Philadelphia: Lippincott-Raven Publishers, 1998:29-39.
3. Mattson RH. General principles: selection of antiepileptic drug therapy. In: Levy RH, Mattson RH, Meldrum BS, ed. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:123-35.
4. Loscher W, Honack D, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. 3. Pentylenetetrazole seizure models. Epilepsy Res 1991;8:171-89.
5. Snead OC. Pharmacological models of generalized absence seizures in rodents. J Neural Transm 1992;35:7-19.
6. Marescaux C, Vergnes M. Genetic absence epilepsy in rats from Strasbourg (GAERS). Ital J Neurol Sci 1995;16:113-8.
7. B receptor activation in absence seizures of lethargic (lh/lh) mice. Science 1992;257:398-401.
8. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38:408-14.
9. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223-86.
10. Macdonald RL, Meldrum BS. General principles. Principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 61-77.
11. Meldrum B. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy. Epilepsy Res Suppl 1996;11: 67-77.
12. White HS. Mechanisms of antiepileptic drugs. In: Porter R, Chadwick D, eds. Epilepsies II. Boston: Butterworth-Heinemann, 1997: 1-30.
13. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(suppl 2):S2-12.
14. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential-and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989;30:286-94.
15. White HS, Woodhead JH, Franklin MR, Swinyard EA, Wolf HH. General principles: experimental selection, quantification, and evaluation of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:99-110.
16. Coulter DA, Hugenard JR, Prince DA. Characterization of ethosuximide reduction of low threshold calcium current in thalamic neurons. Ann Neurol 1989;25:582-93.
17. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium in rat nodose neurons. Neurosci Lett 1990;116:233-8.
18. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989;25:213-20.
19. Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(suppl 1): S2-9.
20. Sofia RD, Felbamate. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:791-7.
21. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27-34.
22. Wlaz P, Loscher W. Anticonvulsant activity of felbamate in amygdala kindling model of temporal lobe epilepsy in rats. Epilepsia 1997;38:1167-72.
23. Pisani A, Stefani A, Siniscalchi A, Mercuri NB, Bernardi G, Calabresi P. Electrophysiological actions of felbamate on rat striatal neurones. Br J Pharmacol 1995;116:2053-61.
24. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997;38:959-65.
25. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia RD, Vogel JR. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993;26:1248-52.
26. 3H]DCKA-labeled strychnine-insensitive glycine receptors in human postmortem brain. Exp Neurol 1994;129:244-50.
27. Wallis RA, Panizzon KL. Glycine reversal of felbamate hypoxic protection. Neuroreport 1993;4:951-4.
28. White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995;20:41-8.
29. A receptors. Ann Neurol 1994;35:229-34.
30. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for partial seizures. Neurology 1995; 45:456-60.
31. Taylor CP. Gabapentin. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:829-41.
32. Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997;28:63-72.
33. Taylor CP, Gee NS, Su T-Z, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29: 233-49.
34. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. Gabapentin increases brain gamma-aminobutyric acid levels in patients with epilepsy. Ann Neurol 1995;38:295-6.
35. 2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
36. Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug, I: anticonvulsant profile in mice and rats. Epilepsia 1986;27: 483-9.
37. Yuen AWC. Lamotrigine: a review of antiepileptic efficacy. Epilepsia 1994;35(suppl 5):S33-6.
38. Buchanan N. Lamotrigine in the treatment of absence seizures. Acta Neurol Scand 1995;92:348.
39. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug, II: neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-7.
40. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993; 266:829-35.
41. Dam M, Ostergaard LH. Other antiepileptic drugs. Oxcarbazepine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:987-95.
42. Gram L, Philbert A. Oxcarbazepine. In: Meldrum BS and Porter RJ, eds. New anticonvulsant drugs. London: John Libbey, 1986: 229-35.
43. Houtkooper MA, Lammertsma A, Meyer JMA, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
44. Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1:284-9.
45. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6.
46. Jensen PK, Gram L, Schmutz M. Oxcarbazepine. Epilepsy Res 1991;3:135-40.
47. Schmutz M, Ferret T, Heckendom R, Jeker A, Portet CH, Olpe HR. GP 47779, the main human metabolite of oxcarbazepine (Trileptal), and both enantiomers have equal anticonvulsant activity [Abstract]. Epilepsia 1993;34(suppl 2):122.
48. Baltzer V, Schmutz M. Experimental anticonvulsant properties of GP 47680 and of MHD, its main human metabolite: compounds related to carbamazepine. In: Meinardi H, Rowan AJ, eds. Advances in epileptology. Amsterdam: Swets & Zeitlinger, 1978:295-9.
49. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
50. McLean MJ, Schmutz M, Wamil AW, Olpe II-R, Portet C, Feldmann KF. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35(suppl 3):S5-9.
51. Wamil AW, Porter C, Jensen PK, Schmutz M, McLean MJ. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture [Abstract]. Epilepsia 1991;32(suppl 3):65.
52. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;23:167-79.
53. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35(suppl 2):450-60.
54. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996;24:73-7.
55. Nakamura J, Tamura S, Kanda T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994;254:83-9.
56. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia [in press].
57. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons [Abstract]. Epilepsia 1993;34(suppl 2):123.
58. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997; 231:123-6.
59. Seven L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons [Abstract]. Epilepsia 1995;36(suppl 4):S38.
60. Skradski S, White HS. The novel antiepileptic drug topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia [in press].
61. A receptors. Science 1995;269:977-81.
62. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-26.
63. Vergnes M, Marescaux C. Pathophysiological mechanisms underlying genetic absence epilepsy in rats. In: Malafosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R, eds. Idiopathic generalized epilepsies: clinical experimental and genetic aspects. London: John Libbey, 1994:151-68.
64. Seino M, Naruto S, Ito T, Miyazaki H. Other antiepileptic drugs. Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:1011-23.
65. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989;3:138-43.
66. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-8.
67. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7.
68. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5:115-9.
69. 3H]Zonisamide binding in rat brain. Jpn J Psychiatry Neurol 1998;42:640-2.